Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
The profitability metrics demonstrate notable fluctuations over the observed period. Generally, gross and operating profit margins exhibited an increasing trend through the first three years, followed by some volatility. However, net profit margin and returns on equity and assets experienced more pronounced shifts, particularly in the latter half of the period.
- Gross Profit Margin
- The gross profit margin generally increased from 67.97% in April 2022 to a peak of 69.20% in April 2023, indicating improving efficiency in production and cost of goods sold management. It remained relatively stable between 69.05% and 69.07% for three consecutive quarters before declining slightly to 67.88% by December 2025. This suggests a sustained ability to maintain profitability at the gross level, with a minor recent dip.
- Operating Profit Margin
- Similar to the gross profit margin, the operating profit margin showed an upward trajectory, rising from 23.76% to 25.61% by July 2023. A subsequent decrease to 23.42% in December 2023 was observed, followed by a strong recovery, reaching 26.85% in December 2025. This indicates effective management of operating expenses, with a recent significant improvement in operational efficiency.
- Net Profit Margin
- The net profit margin displayed the most significant variability. It decreased from 20.90% in April 2022 to 18.90% in December 2022. A dramatic increase occurred in October 2023, reaching 39.58% and peaking at 44.92% in March 2024. Subsequently, it declined sharply to 15.84% in December 2024 before recovering to 28.46% by December 2025. This suggests the influence of non-operating factors, such as tax rates or one-time gains/losses, on overall profitability.
- Return on Equity (ROE)
- The ROE mirrored the trend in net profit margin, decreasing from 26.54% to 23.36% in the initial period. A substantial increase was then observed, peaking at 51.11% in December 2023 and 54.95% in March 2024. A decline to 19.68% in December 2024 was followed by a recovery to 32.87% in December 2025. This indicates a strong correlation between net income and shareholder equity, with significant fluctuations driven by changes in net profitability.
- Return on Assets (ROA)
- The ROA followed a similar pattern to ROE and net profit margin, starting at 11.12% and decreasing to 9.57% before experiencing a substantial rise to 20.98% in December 2023. A subsequent decline to 7.81% in December 2024 was observed, followed by a recovery to 13.46% in December 2025. This suggests that the company’s ability to generate profit from its assets is closely tied to its overall net profitability.
In summary, while gross and operating profitability demonstrated consistent improvement initially, the net profit margin, ROE, and ROA were subject to considerable volatility, particularly in the latter part of the period. The significant increases in these metrics during late 2023 and early 2024, followed by declines, warrant further investigation to understand the underlying drivers of these fluctuations.
Return on Sales
Return on Investment
Gross Profit Margin
| Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Gross profit | |||||||||||||||||||||
| Sales to customers | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Gross profit margin = 100
× (Gross profitQ4 2025
+ Gross profitQ3 2025
+ Gross profitQ2 2025
+ Gross profitQ1 2025)
÷ (Sales to customersQ4 2025
+ Sales to customersQ3 2025
+ Sales to customersQ2 2025
+ Sales to customersQ1 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The gross profit margin exhibited a generally stable pattern over the observed period, with some fluctuations. Initially, the margin demonstrated a slight downward trend from 67.97% in April 2022 to 67.26% in December 2022. However, a subsequent upward trajectory was observed, peaking at 69.20% in April 2023. This was followed by a period of relative stability, with the margin fluctuating between approximately 68.00% and 69.07% through September 2024. More recently, a modest decline is apparent, with the margin decreasing to 67.88% by December 2025.
- Overall Trend
- The gross profit margin generally remained within a narrow range of 67% to 69% throughout the analyzed timeframe. While short-term fluctuations occurred, no significant or sustained deviations from this range were evident. The latter part of the period shows a slight downward drift, but remains within the historical range.
- Short-Term Fluctuations
- A noticeable increase in the gross profit margin occurred between December 2022 (67.26%) and April 2023 (69.20%). This suggests potential improvements in cost of goods sold or pricing strategies during that period. Conversely, a slight decrease occurred between April 2023 and December 2025, indicating a potential reversal of those factors.
- Recent Performance
- The most recent quarterly values indicate a slight decrease in the gross profit margin. From September 2024 (69.05%) to December 2025 (67.88%), the margin declined by 1.17 percentage points. This warrants further investigation to determine the underlying causes, such as increased input costs, pricing pressures, or changes in product mix.
- Relationship to Sales
- While the gross profit margin fluctuated, it generally remained consistent despite variations in sales to customers. Sales decreased significantly in the first half of 2023, but the gross profit margin increased during that same period. This suggests that the company was able to maintain profitability even with lower sales volume, potentially through cost control measures. The increase in sales in the latter part of the period did not significantly impact the gross profit margin.
Operating Profit Margin
| Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Operating earnings | |||||||||||||||||||||
| Sales to customers | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Operating profit margin = 100
× (Operating earningsQ4 2025
+ Operating earningsQ3 2025
+ Operating earningsQ2 2025
+ Operating earningsQ1 2025)
÷ (Sales to customersQ4 2025
+ Sales to customersQ3 2025
+ Sales to customersQ2 2025
+ Sales to customersQ1 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The operating profit margin exhibited a generally positive trend over the observed period, although with some fluctuations. Initial values ranged in the mid-23% range before increasing and then experiencing a decline towards the end of the period.
- Initial Period (Apr 3, 2022 – Dec 31, 2022)
- The operating profit margin began at 23.76% and demonstrated relative stability, fluctuating between 23.47% and 24.63% throughout this timeframe. A slight upward trend is discernible, culminating in a peak of 24.63% in the December 2022 quarter.
- Subsequent Increase (Apr 2, 2023 – Sep 28, 2025)
- Following the initial period, the operating profit margin experienced a more pronounced increase, reaching 25.21% in April 2023 and peaking at 26.85% in December 2025. This suggests improved operational efficiency or pricing power during this phase. The margin consistently remained above 25% for most of this period, with a notable high point in September 2025 at 25.44%.
- Recent Decline (Dec 28, 2025)
- The most recent quarter observed, ending December 28, 2025, shows a decrease in the operating profit margin to 26.85%. This represents a decline from the previous high, warranting further investigation into potential contributing factors such as increased costs or decreased sales prices.
- Overall Trend
- Despite the recent decline, the overall trend indicates an improvement in operating profitability over the analyzed period. The operating profit margin generally increased from approximately 23.5% to nearly 27%, demonstrating a strengthening of the company’s core business performance. However, the final data point suggests a potential shift in this trend that requires monitoring.
The fluctuations observed throughout the period suggest sensitivity to underlying business conditions. Continued monitoring of this metric, alongside related financial indicators, is recommended to fully understand the drivers of these changes and assess the sustainability of the observed profitability improvements.
Net Profit Margin
| Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net earnings (loss) | |||||||||||||||||||||
| Sales to customers | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Net profit margin = 100
× (Net earnings (loss)Q4 2025
+ Net earnings (loss)Q3 2025
+ Net earnings (loss)Q2 2025
+ Net earnings (loss)Q1 2025)
÷ (Sales to customersQ4 2025
+ Sales to customersQ3 2025
+ Sales to customersQ2 2025
+ Sales to customersQ1 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The net profit margin exhibited considerable fluctuation throughout the observed period. Initial values demonstrated a generally decreasing trend from April 2022 through December 2022, followed by significant volatility and a subsequent upward trajectory.
- Initial Decline (Apr 3, 2022 – Dec 31, 2022)
- The net profit margin began at 20.90% in April 2022 and decreased to 18.90% by December 2022. This represents a consistent, though moderate, decline over the eight-month period. The decrease suggests potential pressures on profitability, possibly stemming from increased costs or pricing challenges.
- Significant Volatility & Recovery (Apr 2, 2023 – Dec 31, 2023)
- A substantial disruption occurred in the first quarter of 2023, with the net profit margin falling to -13.77% in April 2023. This was followed by a dramatic increase to 39.58% in October 2023, and a subsequent decrease to 41.28% in December 2023. This period indicates a significant event impacting earnings, followed by a strong recovery, potentially due to one-time gains or cost-cutting measures. The large swing suggests a non-recurring item significantly influenced the results.
- Stabilization & Continued Improvement (Apr 2, 2024 – Dec 28, 2025)
- From April 2024 through December 2025, the net profit margin generally trended upwards, reaching 28.46% by the end of the period. The margin stabilized in the 24% to 27% range for much of 2024 and 2025, indicating a sustained improvement in profitability. The values in this period are notably higher than those observed in 2022 and early 2023. The consistent increase suggests successful implementation of strategies to enhance profitability.
- Peak Performance
- The highest net profit margin recorded during the analyzed timeframe was 44.92% in March 2024, followed closely by 43.91% in June 2024. These values represent peak performance and warrant further investigation to understand the contributing factors.
Overall, the net profit margin demonstrates a complex pattern of decline, extreme volatility, and eventual sustained improvement. The period from October 2023 to December 2025 shows a clear positive trend, suggesting successful adaptation to market conditions and effective financial management.
Return on Equity (ROE)
| Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net earnings (loss) | |||||||||||||||||||||
| Total Johnson & Johnson shareholders’ equity | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| ROE1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
ROE = 100
× (Net earnings (loss)Q4 2025
+ Net earnings (loss)Q3 2025
+ Net earnings (loss)Q2 2025
+ Net earnings (loss)Q1 2025)
÷ Total Johnson & Johnson shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
Return on Equity (ROE) exhibited considerable fluctuation throughout the analyzed period, spanning from April 2022 to December 2025. Initial values demonstrated a generally decreasing trend through the first half of 2023, followed by a substantial surge in the latter half of 2023 and into early 2024. Subsequently, ROE experienced a decline before stabilizing and showing a modest upward trend towards the end of the observation period.
- Initial Decline (Apr 2022 - Jul 2023)
- ROE began at 26.54% in April 2022 and decreased to 24.05% in July 2022, then slightly recovered to 25.68% in October 2022 before falling to 23.36% by December 2022. This downward trajectory continued into the first half of 2023, reaching 17.95% in April 2023 and 17.37% in July 2023. This period suggests a weakening in the profitability relative to shareholder equity.
- Significant Increase (Oct 2023 - Mar 2024)
- A dramatic increase in ROE is observed beginning in October 2023, reaching 48.61%. This increase continued into December 2023 (51.11%) and peaked in March 2024 at 54.95%. This substantial rise indicates a significant improvement in the company’s ability to generate profits from shareholder investments. The large increase in October 2023 is particularly noteworthy.
- Subsequent Moderation (Apr 2024 - Sep 2025)
- Following the peak in March 2024, ROE decreased to 53.14% in April 2024 and 20.93% in July 2024. It then stabilized, fluctuating between 19.68% and 27.92% through December 2024. A gradual upward trend is then apparent, with ROE reaching 31.69% in September 2025 and concluding at 32.87% in December 2025. This suggests a return to more sustainable profitability levels after the exceptional performance in late 2023 and early 2024.
- Correlation with Net Earnings
- The fluctuations in ROE closely mirror the trends in net earnings. The decline in ROE through mid-2023 corresponds with lower net earnings during that period. The substantial increase in ROE in late 2023 and early 2024 aligns with a significant increase in net earnings in October 2023. The subsequent moderation in ROE reflects the more moderate net earnings figures observed in later periods.
- Shareholder Equity Impact
- While net earnings are a primary driver, changes in total shareholder equity also influence ROE. The observed fluctuations in shareholder equity, though less dramatic than those in net earnings, contribute to the overall ROE trends. The increase in shareholder equity throughout the period partially offsets the impact of fluctuating net earnings.
Return on Assets (ROA)
| Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net earnings (loss) | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| ROA1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
ROA = 100
× (Net earnings (loss)Q4 2025
+ Net earnings (loss)Q3 2025
+ Net earnings (loss)Q2 2025
+ Net earnings (loss)Q1 2025)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The Return on Assets (ROA) exhibited considerable fluctuation over the analyzed period, spanning from April 2022 to December 2025. Initial values demonstrated a generally stable, high-single-digit to low-double-digit performance, followed by a period of volatility and a subsequent rise to significantly higher levels, before settling into a more moderate range.
- Initial Performance (Apr 2022 - Dec 2022)
- ROA began at 11.12% in April 2022 and experienced a gradual decline to 9.57% by December 2022. While a slight decrease was observed, the ratio remained consistently above 10% for the majority of this period, indicating a relatively strong ability to generate earnings from its asset base.
- Significant Volatility & Peak (Apr 2023 - Oct 2023)
- A substantial shift occurred in the following quarters. ROA decreased sharply to 6.49% in April 2023, followed by a modest recovery to 6.81% in July 2023. However, a dramatic increase was then recorded in October 2023, reaching 20.85%, and continued to 20.98% in December 2023. This surge suggests a significant improvement in profitability relative to the asset base, potentially driven by extraordinary gains or asset restructuring.
- Moderation & Recent Trend (Dec 2023 - Dec 2025)
- Following the peak, ROA moderated, decreasing to 22.37% in March 2024, 20.99% in June 2024, and then declining further to 8.24% in September 2024. The ratio stabilized somewhat, fluctuating between 7.81% and 13.46% over the final quarters of the period. The most recent value, recorded in December 2025, is 13.46%, indicating a return to a more sustainable, though lower, level of profitability compared to the peak observed in late 2023.
The considerable variance in ROA throughout the period warrants further investigation to understand the underlying drivers of these fluctuations. The substantial increase in October 2023, followed by a subsequent decline, suggests the impact of non-recurring events or strategic shifts in asset management. The recent stabilization indicates a potential normalization of performance, but continued monitoring is recommended.